Are generic drugs delayed to market by so-called “pay-for-delay” deals between brand and generic drug manufacturers? PBS NewsHour Weekend investigated these deals and other practices that opponents like the Federal Trade Commission say are meant to impede generic competition and protect profits. PBS NewsHour Weekend profiled Karen Winkler, a 46-year-old mother of three with Multiple Sclerosis. A deal was struck over her M.S. drug that opponents say delayed the generic to market. Then, the manufacturer raised the price to get patients to switch to its new extended-release version. Unable to afford it, Karen went off the drug until it went generic in 2012. PBS NewsHour Weekend shed light on complicated, secretive pharmaceutical deals rarely examined on national TV. These deals affect thousands of patients, but few know anything about them. And in cases like Winkler's, they can have profound consequences.